GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » Cyclically Adjusted Book per Share

ATXS (Astria Therapeutics) Cyclically Adjusted Book per Share : $55.87 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Astria Therapeutics's adjusted book value per share for the three months ended in Mar. 2025 was $3.437. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $55.87 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Astria Therapeutics's average Cyclically Adjusted Book Growth Rate was 16.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-07-06), Astria Therapeutics's current stock price is $5.81. Astria Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $55.87. Astria Therapeutics's Cyclically Adjusted PB Ratio of today is 0.10.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Astria Therapeutics was 0.10. The lowest was 0.00. And the median was 0.00.


Astria Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Astria Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astria Therapeutics Cyclically Adjusted Book per Share Chart

Astria Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 48.26 57.00

Astria Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.98 47.14 46.23 57.00 55.87

Competitive Comparison of Astria Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Astria Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astria Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Astria Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Astria Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Astria Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astria Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.437/134.9266*134.9266
=3.437

Current CPI (Mar. 2025) = 134.9266.

Astria Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 265.051 100.684 355.195
201509 233.506 100.392 313.833
201512 198.012 99.792 267.727
201603 162.984 100.470 218.879
201606 128.180 101.688 170.078
201609 118.524 101.861 156.999
201612 92.631 101.863 122.698
201703 71.937 102.862 94.361
201706 57.467 103.349 75.026
201709 40.987 104.136 53.106
201712 29.929 104.011 38.825
201803 26.717 105.290 34.237
201806 38.693 106.317 49.105
201809 34.222 106.507 43.354
201812 29.363 105.998 37.377
201903 26.028 107.251 32.745
201906 22.513 108.070 28.108
201909 19.597 108.329 24.408
201912 17.239 108.420 21.454
202003 18.006 108.902 22.309
202006 16.213 108.767 20.112
202009 14.737 109.815 18.107
202012 12.151 109.897 14.918
202103 -25.915 111.754 -31.288
202106 2.895 114.631 3.408
202109 2.616 115.734 3.050
202112 1.991 117.630 2.284
202203 1.021 121.301 1.136
202206 0.232 125.017 0.250
202209 1.046 125.227 1.127
202212 4.539 125.222 4.891
202303 4.146 127.348 4.393
202306 3.749 128.729 3.930
202309 3.179 129.860 3.303
202312 3.602 129.419 3.755
202403 4.962 131.776 5.081
202406 4.584 132.554 4.666
202409 4.365 133.029 4.427
202412 3.968 133.157 4.021
202503 3.437 134.927 3.437

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Astria Therapeutics  (NAS:ATXS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Astria Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.81/55.87
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Astria Therapeutics was 0.10. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Astria Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Astria Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 10th Floor, Boston, MA, USA, 02210
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Executives
Christopher Morabito officer: Chief Medical Officer C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews officer: Chief Business Officer C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Andrew Komjathy officer: Chief Commercial Officer CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols officer: Chief Scientific Officer C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp director, 10 percent owner C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck director C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole director C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger officer: Secretary and General Counsel ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142